CATEGORIES
Supporting innovation in 2021
COVID-19 is likely to impact India’s economy across all industries and business formats. Nevertheless, the biosuppliers sector is gearing up to adopt the new normal and is all set to launch new products in next 12 months in 2021. The upcoming products are spread across a wide range of applications for the life sciences industry such as cell imaging, sample analysis, nanotechnology, gene sequencing, microbiology research, microencapsulation and much more.
IIT-Kgp develops economical device for COVID-19 testing
Covirap, the diagnostic machine developed by the Indian Institute of Technology, Kharagpur (IIT-Kgp) researchers, has been successfully validated for its efficacy in COVID-19 detection by the Indian Council of Medical Research (ICMR).
Medtech startup EzeRx gathers Rs 1.75 Cr in seed round
Medtech startup EzeRx from Kolkata has secured Rs 1.75 crore in a seed funding round backed by the Odisha based KIIT Technology Business Incubator (TBI).
IISER-Pune focuses on checking asymptomatic COVID-19 cases
Researchers from the Indian Institute of Science Education and Research IISER) in Pune, along with the BJ Medical College in Ahmedabad have developed a fast and sensitive device that can help detect asymptomatic COVID-19 patients by testing their sense of smell.
IIHMR, John Hopkins initiate vaccine economics course
With COVID-19 dramatically altering vaccine decision making globally, the world is faced with new challenges on how to maintain routine vaccine coverage and plan the rapid deployment of a coming COVID-19 vaccine.
WHO Pushes Availability Of Covid-19 Rapid Tests For LMICs
A set of agreements to make available, for low and middle-income countries (LMICs), affordable, high-quality COVID-19 antigen rapid tests have been announced by the Access to COVID-19 Tools (ACT) Accelerator.
Is COVID-19 Sidelining NCDs?
The pandemic has affected the supervision of non-communicable diseases (NCDs) not only in terms of overshadowing their severity and hazards but also in prioritization of their therapeutic consideration. Although a number of initiatives are being carried out by the industry and government to address this, there is also the urgent need to build a national strategic framework for managing NCDs during a pandemic.
“We have 18 international patents granted for Stempeucel pooling technology”
Bengaluru based Stempeutics Research has received regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel in India.
Virtual Clinical Trials – An approach whose time has come
The COVID-19 pandemic will surely go down as a major event of the century and an event that will leave a long-lasting impression on our way of living and working.
REGULATE MEDICAL AESTHETICS
The market that is worth billions of dollars in India has witnessed significant growth in the demand for aesthetic procedures owing to the rise in the number of doctors and surgeons providing effective medical aesthetic treatments and the launch of technologically advanced products for the same. However, India lacks proper guidelines to regulate the use of specific products and procedures for aesthetic treatment.
IIT-M makes nano-coated Mg alloys to fix bone fractures
Indian Institute of Technology, Madras (IIT-M) researchers have developed nano-coated magnesium (Mg) alloys that can repair bone defects in rabbits.
IIT-D partners with ILBS for enhancing medical research
(IIT-D) and (ILBS), Delhi has signed a Memorandum of Understanding (MoU)
Dr Reddy's Laboratories to supply 100 M doses of Sputnik V vaccine to India
Supply to Dr Reddy’s 100 Million Doses of The Vaccine.
Hester Bio acquires Brucella vaccine technology from IVRI
Agreement Hester Biosciences has signed
Diabetes Specialist Nurses – future ready health coaches
This World Diabetes Day (November 14, 2020) with the theme ‘Diabetes: Nurses Make The Difference’ focuses on empowering Diabetes Specialist Nurses (DSNs) to improve patient outcomes and deliver cost-effective diabetes care. Today nurses are increasingly becoming ‘health coaches’ and in future, they will play a significant role in preventive medicine.
Securing India's Pharma Industry From Cyber Risk
Increasing production in pharma manufacturing implies a higher convergence of IT and OT systems. While convergence between IT and OT brings about efficiency, it also expands the attacks surface. The only way to make this work safely is to have a unified, risk-based view of the IT and OT environments.
India Bracing For Mental Health Crisis
This year, the 29th World Mental Health Day is all the more important for the globe as we find ourselves in the midst of a global mental distress crisis brought by COVID-19. The theme ‘Mental Health for All: Greater Investment- Greater Access’ fits appropriately as the situation not only demands enhanced access to mental health by breaking the stigma but also strengthening investments in the space as supporting pillars.
“We have the capacity to produce over 10M COVID-19 tests per week globally”
Thermo Fisher Scientific, the world leader in serving science, is continuously working to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments.
“We are in talks with Karnataka to deploy Vevra pods across the state”
To fight the ongoing pandemic and other contagious and airborne diseases, Bengaluru based company Vevra has allied with a Portugal based healthcare IoT company InnoWave Group to introduce artificial intelligence (AI) driven mobile hospital units called Vevra Pods. Primarily born as an answer for major medical crises of any form, these pods consist of a set of movable capsules that aim to efficiently assist in the infrastructure of hospitals across India. Mahesh Krishnahari, Director & Founder, Vevra Group, Bengaluru spoke to BioSpectrum in detail about this innovative solution. Edited excerpts;
“The biotechnology industry in India is entering a new era of growth”
The COVID-19 pandemic has unlocked several opportunities for the life sciences sector in India. And in response to this, the sector has taken the right plunge. KPMG’s new report on ‘Site selection for life sciences in Asia’ reveals the true potential has India possess. In an interview, Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG, Mumbai, expounds on the key findings of this study and shares insights on key market drivers. Edited excerpts;
Technology Adding Fuel To Drive Out Covid-19
The pressure on the healthcare sector to provide a solution for the COVID-19 pandemic is massive. As a result, the life sciences sector is adopting new technologies to quickly devise a way out to beat this crisis. Many companies and academic institutions in India are moving headfirst in this direction with support from the technology sector both locally and globally. Technology adoption is indeed playing a key role in better understanding and addressing the crisis with the right amount of fuel being added by the tech giants.
“We aim to make molecular diagnostics based on RT-PCR technology mainstream in India”
Backed by Serum Institute of India, Pune based startup Mylab Discovery Solutions is aggressively launching new products in the diagnostic testing space to overcome the challenges posed by the pandemic. After raising funds from the Department of Biotechnology (DBT) and few private investors, the Mylab team has recently developed a fully-automated sample to-PCR-ready system for molecular diagnostics, which is a first in India. Founded in 2016, it is the first company in Asia and second company worldwide to develop and manufacture FDA approved ID-NAT kits for accurate detection of HIV, HBV, HCV and other infections. BioSpectrum India got in touch with Hasmukh Rawal, Managing Director, Mylab Discovery Solutions to find out more about the initiatives being taken up by the startup to combat COVID-19. Edited excerpts;
“Biotech will get woven into more diverse science education programmes”
Aiming to make India a global knowledge superpower, the government has recently announced the new National Education Policy (NEP) 2020. Being the first education policy of the 21st century, it is set to address the many growing developmental imperatives of our country. And out of these many imperatives, bridging the skill gaps in the biotechnology industry is one of them. To explore how NEP 2020 can benefit the biotechnology/life sciences (BT/LS) education in India, BioSpectrum interacted with Dr Ramgopal Rao S, Academic Manager, Biocon Academy, Bengaluru. Edited excerpts;
Reviving trends for healthcare economy
While COVID-19 has wreaked havoc on the larger economy, the healthcare sector is no exception. With healthcare sector experiencing operating loss to the tune of Rs 14,000 to 24,000 crore for the first quarter with private sector reporting a 90 per cent drop in revenue, it has been a roller-coaster of a ride so far.
SCHOTT AG delivers vials to package 2 Bn doses of COVID-19 vaccines
German glass manufacturing giant SCHOTT AG is supporting the world’s fight against COVID-19 with vials capable of holding up to 2 billion vaccination doses.
Mylan receives DCGI approval for TB drug pretomanid
Mylan, a global pharmaceutical company, recently announced that the Drug Controller General of India (DCGI) has approved the anti-tuberculosis drug pretomanid for conditional access under the National Tuberculosis Elimination Programme (NTEP), making India the second country in the world to provide regulatory approval for this product.
INDIA INCHING TO BE GLOBAL PPE HUB
According to a report by Invest India, the domestic PPE industry grew 56 times in a span of 60 days. On March 1, two days before the World Health Organization (WHO) spoke of a global shortage of PPE, India had no PPE coveralls suitable for COVID-19. But a clear roadmap and prompt assistance by the Ministry of Textiles and all its allied bodies, ensured India becomes a world leader in PPE manufacturing amid a global shortage.
Gennova develops mRNA vaccine against COVID-19
The Department of Biotechnology (DBT) has facilitated the establishment of the first-of-its-kind mRNA based vaccine manufacturing platform in India.
Abbott joins hands with 1mg for CGM solutions
In a move to expand access and empower Indian patients to take charge of their health, American multinational medical devices and healthcare company Abbott and Gurugram based online pharmacy and healthcare startup 1mg have recently announced their collaboration to make Abbott’s continuous glucose monitoring (CGM) products available online, including its professional flash glucose monitoring system, FreeStyle Libre Pro.
A case of lost credibility?
The revelation was not merely shocking but was hitting the core of confidence built up among the professionals over the years by ‘The Lancet’ and the ‘New England Journal of Medicine’. The editors of the two prestigious medical journals appeared to have expressed their exasperation over the pressure put by pharma companies. They seemed to have used the word ‘criminal’ to describe the erosion of science in the process.